Multi‐target anti‐EBV therapy for prevent primary infection in kidney transplant recipients from deceased donor, at risk of post transplantation lymphoproliferative disorder (EBV D+/R‐) - Archive ouverte HAL Access content directly
Journal Articles Transplant International Year : 2020

Multi‐target anti‐EBV therapy for prevent primary infection in kidney transplant recipients from deceased donor, at risk of post transplantation lymphoproliferative disorder (EBV D+/R‐)

(1) , (2)
1
2

Abstract

If all immunocompromised patients can experience Post Transplantation Lymphoproliferative Disorder (PTLD) due to EBV reactivation, EBV-seronegative recipients in which primary infection can occur, are at higher risk of developing PTLD when transplanted with an organ from an EBV seropositive donor(1,2). In our center, among 73 EBV-seronegative adult patients transplanted between 2000 and 2016 (3% of the whole), 8 developed an early PTLD and 5 others beyond one year, all EBV-related(3). EBV is most often latent and inaccessible within B cells, but occasionally it achieves a lytic infection, susceptible to some antiviral drugs, such as (val)ganciclovir, and specific antibodies.

Dates and versions

inserm-02633092 , version 1 (27-05-2020)

Identifiers

Cite

Simon Ville, Jacques Dantal. Multi‐target anti‐EBV therapy for prevent primary infection in kidney transplant recipients from deceased donor, at risk of post transplantation lymphoproliferative disorder (EBV D+/R‐). Transplant International, 2020, ⟨10.1111/tri.13652⟩. ⟨inserm-02633092⟩
10 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More